Firebrick Pharma Ltd
ASX:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Firebrick Pharma Ltd
Cash & Cash Equivalents
Firebrick Pharma Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
Cash & Cash Equivalents
AU$983.4k
|
CAGR 3-Years
-48%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash & Cash Equivalents
AU$365.3k
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash & Cash Equivalents
AU$59.8m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash & Cash Equivalents
AU$4.2m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-13%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash & Cash Equivalents
AU$47.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash & Cash Equivalents
AU$35.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
See Also
What is Firebrick Pharma Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
983.4k
AUD
Based on the financial report for Jun 30, 2025, Firebrick Pharma Ltd's Cash & Cash Equivalents amounts to 983.4k AUD.
What is Firebrick Pharma Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
60%
Over the last year, the Cash & Cash Equivalents growth was 19%. The average annual Cash & Cash Equivalents growth rates for Firebrick Pharma Ltd have been -48% over the past three years , 60% over the past five years .
